EQS-News: Formycon publishes details of a previously undisclosed pipeline project – FYB206 is a biosimilar candidate for Keytruda®* (pembrolizumab)
Press Release // September 19, 2022
- Press Release // September 19, 2022
Munich Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced details of a previously undisclosed project in its development pipeline. - FYB206 is a biosimilar candidate for Keytruda (pembrolizumab) and the development is at an advanced preclinical stage.
- Pembrolizumab binds to the PD-1 receptor and specifically blocks the interaction between PD-1 and its ligand PD-L1.
- Formycon's CSO, Dr. Andreas Seidl, adds: "With FYB206, we have a promising biosimilar candidate in the fast-growing field of immuno-oncology in our development portfolio.